Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000374 · ClinicalTrials.gov registry record · Phase 4
Treatment for First-Episode Schizophrenia
A Phase 4 study of Schizophrenia, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
- 2
- Study locations
NCT00000374: Completed Phase 4 study of Schizophrenia, sponsored by Northwell Health.
NCT00000374 is a Phase 4 study of Schizophrenia that has completed, run by Northwell Health. The registered enrollment target is 125 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (43% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000374, a Phase 4 study of Schizophrenia, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
- 2
- Study locations
Study Summary
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
Conditions Studied
Interventions
- DRUG Risperidone
- DRUG Olanzapine
Study Locations (2)
New York
- Hillside Hospital - Glen Oaks
- Bronx-Lebanon Hospital Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 1998-09 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
What the finished NCT00000374 record still lists
NCT00000374 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Risperidone is the first listed.
NCT00000374 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00000374 about?
NCT00000374 is a clinical study titled "Treatment for First-Episode Schizophrenia". This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
What is the current status of trial NCT00000374?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 1998-09. Estimated completion is 2007-05.
What conditions does trial NCT00000374 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00000374?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00000374?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000374 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000374's enrollment target sits among peer trials
125 116th of 315 higher than 200 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia